I mentioned a few weeks ago the market has some work to do at this level. The past couple of days have been less than exciting. I’m very picky with my entries here. Maybe the INTC earnings gap will lead to some tradeable volatility tomorrow. Options expire Friday, so that could help volatility too.

I had a feeling INTC would gap the market higher (I’m assuming the after hours gap holds), but I didn’t want to hold into earnings. I rarely do hold into earnings. The inverse head and shoulders is about set up. The market has a good chance of heading higher if it moves over that neckline near 2400.

GERN - Geron broke out of a 2-week base on the daily chart. For some reason my chart is not showing the candlestick.

There should be plenty of news catalysts to get things going the next few months, including news today.

‘The Food and Drug Administration looks like it’s bowing to the inevitable this week and drawing the blueprint for the first-ever human experiments with human embryonic stem cells.

FDA advisors meet Thursday and Friday to begin to design how these embryonic stem cell tests will be conducted. It’s an important regulatory step that could lead to human testing as early as this year. So far, biotechs have tested their spinal-cord drugs in animals, not people.’

The monthly chart produced a hammer for March, followed by an aggressive buy signal with the higher high.